This feature highlights changes in clinical research organizations’ personnel.
Araim Pharmaceuticals has named Ferry Breedveld as acting chief executive officer. Breedveld was formerly a professor of internal medicine specializing in rheumatology at Leiden University until 2015, and currently serves as the chairman of the board for Nij Smellinghe Hospital in the Netherlands.
Arrakis Therapeutics has named Elizabeth Radcliffe vice president of finance and strategy. Radcliffe was most recently vice president of financial planning and analysis at Agios Pharmaceuticals.
Aruvant Sciences has named William Chou chief executive officer. Chou was most recently appointed vice president of global disease and the lead for Novartis’ cell and gene therapy unit.
Axcella Health has expanded its leadership team with the addition of Laurent Chardonnet as chief financial officer and Heidy King-Jones as general counsel. Chardonnet was previously the vice president, treasurer and principal accounting officer, as well as the head of finance and administration for the European Division at the Incyte Corporation. King Jones previously served as the vice president of legal for Axcella Health.
Jeanne Bertonis has been appointed chief operating officer at Azitra. Bertonis was previously chief executive officer and co-founder of Visgo Therapeutics.
Brian Phillips has been appointed chief legal officer at Cerevel Therapeutics. Phillips was previously senior vice president of legal, human resources, IT, and general counsel and secretary for Surmodics, Inc.
CODA Biotherapeutics has bolstered its leadership with the appointment of Annahita Keravala as senior vice president for gene therapy, Orion Keifer as vice president of discovery and translational research, and, Steve Dodson as vice president of pharmacology and early development. Keravala previously served as the associate vice president of the AAV platform at Rocket Pharmaceuticals. Keifer was the senior director of research for CODA Biotherapeutics. Dodson was a senior director for drug discovery and development at Second Genome, Inc before he joined CODA Biotherapeutics.
Entera Bio has appointed Jonathan Lieber chief financial officer. Lieber last served as the CFO of Histogenics and serves as a managing director at Danforth Advisors.
ILiAD Biotechnologies has expanded its senior management team with the appointment of Cheryl Keech as chief medical officer and executive vice president. Keech was most recently executive medical director at PPD.
Paul Woodard has been named chief medical officer, and An Song as chief scientific officer at Immune-Onc Therapeutics. Woodard previously served as the senior vice president of clinical and medical affairs at Immune-Onc Therapeutics. Song was the senior vice president of developmental sciences at Immune-Onc Therapeutics.
Klaus Lindpaintner has been named chief medical officer and chief science officer at InterVenn Biosciences. Lindpaintner brings experience from his previous role as vice president and global head of human genetics and computational biomedicine at Pfizer.
GuangPing Gao has been named chief strategist for gene therapy at IVERIC bio. Gao is currently the president of the American Society of Gene and Cell Therapy.
Kite Pharma, a Gilead company, has announced two new additions to its leadership team with the appointment of Charles Calderaro as global head of technical operations and Ken Takeshita as global head of clinical development. Calderaro was previously the senior vice president of global manufacturing for BioMarin Pharmaceutical. Takeshita served as the senior vice president of clinical research at Sorrento Therapeutics.
Jorge DiMartino has been appointed chief medical officer and executive vice president of clinical development at Kronos Bio. DiMartino was most recently the group medical director for biooncology and exploratory clinical development at Genentech, Inc.
Kymera Therapeutics has named Nello Mainolfi president and chief executive officer. Mainolfi was formerly president and chief scientific officer at Kymera Therapeutics.
Jason Tardio has been appointed chief commercial officer at Ovid Therapeutics. Tardio previously served as the vice president and head of the multiple sclerosis franchise at Novartis.
Susheel Umesh has been appointed chief executive for domestic formulations, Rajeeva Kumar Mangalum as chief operating officer for pharmaceutical operations, and Dinesh Singla as senior vice president of pharmaceutical research and pharmaceutical regulatory affairs at Panacea Biotec. Umesh was previously managing director and general manager for specialty care at Abbott. Mangalum and Singla have both worked at Panacea Biotec Limited for over 10 years each before their promotions.